eFFECTOR Therapeutics, Inc.

Locust Walk Acquisition Corp. (Nasdaq: LWAC) was a blank-check company sponsored by Locust Walk Partners, a life sciences-focused advisory firm, that completed its IPO in 2020 targeting the biopharmaceutical sector. The SPAC pursued a combination with eFFECTOR Therapeutics, Inc., a clinical-stage oncology company developing translation regulator therapies aimed at selective cancer cell targeting. An 8-K filed August 31, 2021 marked a material development in the transaction process as the deal moved toward closing. The combined entity operates in the healthcare and life sciences industry under the eFFECTOR Therapeutics name. Sign up for a full SpacDesk account to access complete filing histories, sponsor profiles, and deal analytics for LWAC and hundreds of other SPACs.